Cargando…

International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature

Somatostatin, also known as somatotropin-release inhibitory factor, is a cyclopeptide that exerts potent inhibitory actions on hormone secretion and neuronal excitability. Its physiologic functions are mediated by five G protein–coupled receptors (GPCRs) called somatostatin receptor (SST)1–5. These...

Descripción completa

Detalles Bibliográficos
Autores principales: Günther, Thomas, Tulipano, Giovanni, Dournaud, Pascal, Bousquet, Corinne, Csaba, Zsolt, Kreienkamp, Hans-Jürgen, Lupp, Amelie, Korbonits, Márta, Castaño, Justo P., Wester, Hans-Jürgen, Culler, Michael, Melmed, Shlomo, Schulz, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society for Pharmacology and Experimental Therapeutics 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6148080/
https://www.ncbi.nlm.nih.gov/pubmed/30232095
http://dx.doi.org/10.1124/pr.117.015388
_version_ 1783356694952148992
author Günther, Thomas
Tulipano, Giovanni
Dournaud, Pascal
Bousquet, Corinne
Csaba, Zsolt
Kreienkamp, Hans-Jürgen
Lupp, Amelie
Korbonits, Márta
Castaño, Justo P.
Wester, Hans-Jürgen
Culler, Michael
Melmed, Shlomo
Schulz, Stefan
author_facet Günther, Thomas
Tulipano, Giovanni
Dournaud, Pascal
Bousquet, Corinne
Csaba, Zsolt
Kreienkamp, Hans-Jürgen
Lupp, Amelie
Korbonits, Márta
Castaño, Justo P.
Wester, Hans-Jürgen
Culler, Michael
Melmed, Shlomo
Schulz, Stefan
author_sort Günther, Thomas
collection PubMed
description Somatostatin, also known as somatotropin-release inhibitory factor, is a cyclopeptide that exerts potent inhibitory actions on hormone secretion and neuronal excitability. Its physiologic functions are mediated by five G protein–coupled receptors (GPCRs) called somatostatin receptor (SST)1–5. These five receptors share common structural features and signaling mechanisms but differ in their cellular and subcellular localization and mode of regulation. SST(2) and SST(5) receptors have evolved as primary targets for pharmacological treatment of pituitary adenomas and neuroendocrine tumors. In addition, SST(2) is a prototypical GPCR for the development of peptide-based radiopharmaceuticals for diagnostic and therapeutic interventions. This review article summarizes findings published in the last 25 years on the physiology, pharmacology, and clinical applications related to SSTs. We also discuss potential future developments and propose a new nomenclature.
format Online
Article
Text
id pubmed-6148080
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher The American Society for Pharmacology and Experimental Therapeutics
record_format MEDLINE/PubMed
spelling pubmed-61480802018-10-01 International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature Günther, Thomas Tulipano, Giovanni Dournaud, Pascal Bousquet, Corinne Csaba, Zsolt Kreienkamp, Hans-Jürgen Lupp, Amelie Korbonits, Márta Castaño, Justo P. Wester, Hans-Jürgen Culler, Michael Melmed, Shlomo Schulz, Stefan Pharmacol Rev IUPHAR Nomenclature Report Somatostatin, also known as somatotropin-release inhibitory factor, is a cyclopeptide that exerts potent inhibitory actions on hormone secretion and neuronal excitability. Its physiologic functions are mediated by five G protein–coupled receptors (GPCRs) called somatostatin receptor (SST)1–5. These five receptors share common structural features and signaling mechanisms but differ in their cellular and subcellular localization and mode of regulation. SST(2) and SST(5) receptors have evolved as primary targets for pharmacological treatment of pituitary adenomas and neuroendocrine tumors. In addition, SST(2) is a prototypical GPCR for the development of peptide-based radiopharmaceuticals for diagnostic and therapeutic interventions. This review article summarizes findings published in the last 25 years on the physiology, pharmacology, and clinical applications related to SSTs. We also discuss potential future developments and propose a new nomenclature. The American Society for Pharmacology and Experimental Therapeutics 2018-10 2018-10 /pmc/articles/PMC6148080/ /pubmed/30232095 http://dx.doi.org/10.1124/pr.117.015388 Text en Copyright © 2018 The Author(s). http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the CC BY Attribution 4.0 International license (http://creativecommons.org/licenses/by/4.0/) .
spellingShingle IUPHAR Nomenclature Report
Günther, Thomas
Tulipano, Giovanni
Dournaud, Pascal
Bousquet, Corinne
Csaba, Zsolt
Kreienkamp, Hans-Jürgen
Lupp, Amelie
Korbonits, Márta
Castaño, Justo P.
Wester, Hans-Jürgen
Culler, Michael
Melmed, Shlomo
Schulz, Stefan
International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
title International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
title_full International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
title_fullStr International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
title_full_unstemmed International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
title_short International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
title_sort international union of basic and clinical pharmacology. cv. somatostatin receptors: structure, function, ligands, and new nomenclature
topic IUPHAR Nomenclature Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6148080/
https://www.ncbi.nlm.nih.gov/pubmed/30232095
http://dx.doi.org/10.1124/pr.117.015388
work_keys_str_mv AT guntherthomas internationalunionofbasicandclinicalpharmacologycvsomatostatinreceptorsstructurefunctionligandsandnewnomenclature
AT tulipanogiovanni internationalunionofbasicandclinicalpharmacologycvsomatostatinreceptorsstructurefunctionligandsandnewnomenclature
AT dournaudpascal internationalunionofbasicandclinicalpharmacologycvsomatostatinreceptorsstructurefunctionligandsandnewnomenclature
AT bousquetcorinne internationalunionofbasicandclinicalpharmacologycvsomatostatinreceptorsstructurefunctionligandsandnewnomenclature
AT csabazsolt internationalunionofbasicandclinicalpharmacologycvsomatostatinreceptorsstructurefunctionligandsandnewnomenclature
AT kreienkamphansjurgen internationalunionofbasicandclinicalpharmacologycvsomatostatinreceptorsstructurefunctionligandsandnewnomenclature
AT luppamelie internationalunionofbasicandclinicalpharmacologycvsomatostatinreceptorsstructurefunctionligandsandnewnomenclature
AT korbonitsmarta internationalunionofbasicandclinicalpharmacologycvsomatostatinreceptorsstructurefunctionligandsandnewnomenclature
AT castanojustop internationalunionofbasicandclinicalpharmacologycvsomatostatinreceptorsstructurefunctionligandsandnewnomenclature
AT westerhansjurgen internationalunionofbasicandclinicalpharmacologycvsomatostatinreceptorsstructurefunctionligandsandnewnomenclature
AT cullermichael internationalunionofbasicandclinicalpharmacologycvsomatostatinreceptorsstructurefunctionligandsandnewnomenclature
AT melmedshlomo internationalunionofbasicandclinicalpharmacologycvsomatostatinreceptorsstructurefunctionligandsandnewnomenclature
AT schulzstefan internationalunionofbasicandclinicalpharmacologycvsomatostatinreceptorsstructurefunctionligandsandnewnomenclature